Clover Health Investments Corp is a healthcare technology company... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MDST | 28.48 | 0.24 | +0.85% |
| Westwood Salient Enhanced Midstream Income ETF (MDST) | |||
| XOEF | 29.82 | 0.18 | +0.62% |
| iShares S&P 500 ex S&P 100 ETF (XOEF) | |||
| HFSI | 33.55 | 0.03 | +0.10% |
| Hartford Strategic Income ETF (HFSI) | |||
| XEY | 20.22 | -0.03 | -0.12% |
| GraniteShares YieldBOOST Ether ETF (XEY) | |||
| SOCL | 43.81 | -0.11 | -0.24% |
| Global X Social Media ETF (SOCL) | |||
A.I.dvisor indicates that over the last year, CLOV has been loosely correlated with ALHC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CLOV jumps, then ALHC could also see price increases.
| Ticker / NAME | Correlation To CLOV | 1D Price Change % | ||
|---|---|---|---|---|
| CLOV | 100% | -1.71% | ||
| ALHC - CLOV | 37% Loosely correlated | -1.53% | ||
| OSCR - CLOV | 31% Poorly correlated | -0.25% | ||
| PGNY - CLOV | 23% Poorly correlated | +0.19% | ||
| CNC - CLOV | 18% Poorly correlated | +0.48% | ||
| HUM - CLOV | 10% Poorly correlated | +0.05% | ||
More | ||||
Industry ManagedHealthCare
The 10-day RSI Oscillator for CLOV moved out of overbought territory on September 15, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 instances where the indicator moved out of the overbought zone. In 32 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLOV as a result. In 65 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CLOV broke above its upper Bollinger Band on September 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Moving Average Convergence Divergence (MACD) for CLOV just turned positive on October 06, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
CLOV moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLOV crossed bullishly above the 50-day moving average on September 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +10.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 222 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 153 of 196 cases where CLOV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.112) is slightly higher than the industry average of (3.247). P/E Ratio (0.000) is within average values for comparable stocks, (139.958). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CLOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.